Characteristics of patients transplanted for HCV cirrhosis randomised to either tacrolimus monotherapy or triple therapy (tacrolimus, prednisolone and azathioprine)
| Monotherapy 49 | Triple therapy 48 | |
|---|---|---|
| Follow-up (median) | ||
| 96 (1–146) m | 91.6 | 98.7 |
| Biopsies performed | ||
| Years 1/2 | 34/27 | 40/30 |
| Years 3/4 | 26/17 | 27/19 |
| Years 5/6 | 18/14 | 16/13 |
| Years 7/8 | 11/9 | 10/9 |
| Years 9/10 | 2/3 | 2/2 |
| Biopsy index* | 3.31 | 3.48 |
| Reaching Ishak stage 4 | ||
| N | 19 | 11 |
| Median | 32 m | 49 m |
| Reaching CPA≥6% | ||
| N | 20/33 (61%) | 13/39 (33%) |
| Median | 41 m | 49 m |
| Reaching CPA≥7.2% | ||
| N | 21/33 | 14/39 |
| Median | 42 m | 51 m |
| Reaching HVPG≥10 mm Hg | ||
| N | 11/33 | 4/31 |
| Decompensated | ||
| n (months) | 9 (70 months) | 4 (91 months) |
| Deaths | ||
| n | 14 | 7 |
*Biopsy index per patient (months of follow-up divided by the number of biopsies from 1 year onwards).
CPA, collagen proportionate area; HVPG, hepatic venous pressure gradient.